Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Real-World Population-Based Observational Study: Comparative Safety of Abatacept in Rheumatoid Arthritis with co-morbid chronic obstructive pulmonary disease

Next Previous
Trial Profile

A Real-World Population-Based Observational Study: Comparative Safety of Abatacept in Rheumatoid Arthritis with co-morbid chronic obstructive pulmonary disease

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abatacept (Primary) ; Adalimumab; Anakinra; Certolizumab pegol; Etanercept; Golimumab; Infliximab; Rituximab; Tocilizumab; Tofacitinib
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions

Most Recent Events

  • 03 Sep 2019 Results assessing safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with chronic obstructive pulmonary disease (COPD), published in the Rheumatology.
  • 15 Jun 2019 Results (n=7,424 new users of biologic DMARDs matched to 7,424 new users of non-biologic DMARDs) presented at the 20th Annual Congress of the European League Against Rheumatism
  • 14 Jul 2018 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top